Hsp90/Cdc37 Chaperone/co-chaperone complex, a novel junction anticancer target elucidated by the mode of action of herbal drug Withaferin A

BMC Bioinformatics

Volumn 12, Issue SUPPL. 1, 2011, Pages

  Grover, Abhinav ^a   Shandilya, Ashutosh ^a   Agrawal, Vibhuti ^a   Pratik, Piyush ^a   Bhasme, Divya ^a   Bisaria, Virendra S ^a   Sundar, Durai ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTATIONAL ANALYSIS; HEAT-SHOCK PROTEIN 90; INDIVIDUAL PROTEINS; MALIGNANT PROGRESSION; MOLECULAR CHAPERONES; MOLECULAR DYNAMICS SIMULATIONS; NATURALLY OCCURRING; SIGNALLING PATHWAYS; COMPUTATIONAL APPROACH; GENETIC INSTABILITY;

ASSOCIATION REACTIONS; BINDING ENERGY; CELL DEATH; DISEASES; MOLECULAR DYNAMICS; THERMODYNAMIC STABILITY; TUMORS; BIOINFORMATICS;

PROTEINS;

WITHANIA SOMNIFERA;

ANTINEOPLASTIC AGENT; CDC37 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CHAPERONIN; HEAT SHOCK PROTEIN 90; LIGAND; WITHAFERIN A; WITHANOLIDE;

ALGORITHM; ARTICLE; BIOLOGY; CHEMISTRY; METHODOLOGY; MOLECULAR DYNAMICS; NEOPLASM; PROTEIN ANALYSIS; PROTEIN BINDING;

ALGORITHMS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE PROTEINS; CHAPERONINS; COMPUTATIONAL BIOLOGY; HSP90 HEAT-SHOCK PROTEINS; LIGANDS; MOLECULAR DYNAMICS SIMULATION; NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; WITHANOLIDES;

EID: 79951519302     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-12-S1-S30     Document Type: Article

References (69)

1. Hartl FU. Molecular chaperones in cellular protein folding. Nature 1996, 381(6583):571-580. 10.1038/381571a0, 8637592.
2. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Bio 2004, 5(10):781-791.
3. Welch WJ. Heat-Shock Proteins Functioning as Molecular Chaperones - Their Roles in Normal and Stressed Cells. Philos T Roy Soc B 1993, 339(1289):327-333.
4. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004, 10(6):283-290. 10.1016/j.molmed.2004.04.006, 15177193.
5. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Clin Cancer Res 2003, 9(16):6126s-6126s.
6. Falsone SF, Gesslbauer B, Tirk F, Piccinini AM, Kungl AJ. A proteomic snapshot of the human heat shock protein 90 interactome. Febs Lett 2005, 579(28):6350-6354. 10.1016/j.febslet.2005.10.020, 16263121.
7. Zhao R, Davey M, Hsu YC, Kaplanek P, Tong A, Parsons AB, Krogan N, Cagney G, Mai D, Greenblatt J, et al. Navigating the chaperone network: an integrative map of physical, genetic, and chemical-genetic interactions mediated by the yeast Hsp90 chaperone system. Febs J 2005, 272:349-349.
8. Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: The explanation remains elusive. Acs Chem Biol 2006, 1(5):279-284. 10.1021/cb600224w, 17163756.
9. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008, 410:439-453. 10.1042/BJ20071640, 18290764.
10. Didelot C, Lanneau D, Brunet M, Joly AL, De Thonel A, Chiosis G, Garrido C. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr Med Chem 2007, 14(27):2839-2847. 10.2174/092986707782360079, 18045130.
11. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008, 13(1-2):38-43. 10.1016/j.drudis.2007.10.007, 18190862.
12. Gress TM, Mullerpillasch F, Weber C, Lerch MM, Friess H, Buchler M, Beger HG, Adler G. Differential Expression of Heat-Shock Proteins in Pancreatic-Carcinoma. Cancer Res 1994, 54(2):547-551.
13. Ferrarini M, Heltai S, Zocchi MR, Rugarli C. Unusual Expression and Localization of Heat-Shock Proteins in Human Tumor-Cells. Int J Cancer 1992, 51(4):613-619. 10.1002/ijc.2910510418, 1601523.
14. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004, 206(2):149-157. 10.1016/j.canlet.2003.08.032, 15013520.
15. McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, Frydman J. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 2007, 131(1):121-135. 10.1016/j.cell.2007.07.036, 17923092.
16. Isaacs JS, Xu WP, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3(3):213-217. 10.1016/S1535-6108(03)00029-1, 12676580.
17. Richter K, Buchner J. Hsp90: Chaperoning signal transduction. J Cell Physiol 2001, 188(3):281-290. 10.1002/jcp.1131, 11473354.
18. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 2003, 228(2):111-133.
19. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5(10):761-772. 10.1038/nrc1716, 16175177.
20. Powers MV, Workman P. Inhibitors of the heat shock response: Biology and pharmacology. Febs Lett 2007, 581(19):3758-3769. 10.1016/j.febslet.2007.05.040, 17559840.
21. Neckers L. Development of small molecule Hsp90 inhibitors: Utilizing both forward and reverse chemical genomics for drug identification. Curr Med Chem 2003, 10(9):733-739. 10.2174/0929867033457818, 12678776.
22. Whitesell L, Mimnaugh EG, Decosta B, Myers CE, Neckers LM. Inhibition of Heat-Shock Protein Hsp90-Pp60(V-Src) Heteroprotein Complex-Formation by Benzoquinone Ansamycins - Essential Role for Stress Proteins in Oncogenic Transformation. P Natl Acad Sci USA 1994, 91(18):8324-8328.
23. Sharma SV, Agatsuma T, Nakano H. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol. Oncogene 1998, 16(20):2639-2645. 10.1038/sj.onc.1201790, 9632140.
24. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001, 61(10):4003-4009.
25. Li YY, Zhang T, Schwartz SJ, Sun DX. New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential. Drug Resist Update 2009, 12(1-2):17-27.
26. Zhang T, Hamza A, Cao XH, Wang B, Yu SW, Zhan CG, Sun DX. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008, 7(1):162-170. 10.1158/1535-7163.MCT-07-0484, 18202019.
27. Gray PJ, Stevenson MA, Calderwood SK. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells. Cancer Res 2007, 67(24):11942-11950. 10.1158/0008-5472.CAN-07-3162, 18089825.
28. Gray PJ, Prince T, Cheng J, Stevenson MA, Calderwood SK. Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer 2008, 8(7):491-495. 2779120, 18511936, 10.1038/nrc2420.
29. Pearl LH. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr Opin Genet Dev 2005, 15(1):55-61. 10.1016/j.gde.2004.12.011, 15661534.
30. Vaughan CK, Gohlke U, Sobott F, Good VM, Ali MMU, Prodromou C, Robinson CV, Saibil HR, Pearl LH. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol Cell 2006, 23(5):697-707. 10.1016/j.molcel.2006.07.016, 16949366.
31. Silverstein AM, Grammatikakis N, Cochran BH, Chinkers M, Pratt WB. P50(cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetratricopeptide repeat binding site. J Biol Chem 1998, 273(32):20090-20095. 10.1074/jbc.273.32.20090, 9685350.
32. Smith JR, Clarke PA, de Billy E, Workman P. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 2009, 28(2):157-169. 2635547, 18931700, 10.1038/onc.2008.380.
33. Winters M. Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology. Alternative Medicine Review 2006, 11(4):269-277.
34. Matsuda H, Murakami T, Kishi A, Yoshikawa M. Structures of withanosides I, II, III, IV, V, VI, and VII, new withanolide glycosides, from the roots of Indian Withania somnifera Dunal. and inhibitory activity for tachyphylaxis to clonidine in isolated guinea-pig ileum. Bioorgan Med Chem 2001, 9(6):1499-1507.
35. Ray A, Gupta M. Withasteroids, a growing group of naturally occurring steroidal lactones. Progress in the chemistry of natural organic products 1994, 63:1-106. New York: Springer-Verlag, W, Kerby G, Moore R, Steglich W, Tamm C.
36. Alhindawi MK, Alkhafaji SH, Abdulnabi MH. Antigranuloma Activity of Iraqi Withania-Somnifera. J Ethnopharmacol 1992, 37(2):113-116. 10.1016/0378-8741(92)90069-4, 1434685.
37. Mishra L, Singh B, Dagenias S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev 2000, 5:334-336.
38. Owais M, Sharad KS, Shehbaz A, Saleemuddin M. Antibacterial efficacy of Withania somnifera (ashwagandha) an indigenous medicinal plant against experimental murine salmonellosis. Phytomedicine 2005, 12(3):229-235. 10.1016/j.phymed.2003.07.012, 15830846.
39. Bhattacharya A, Ghosal S, Bhattacharya SK. Anti-oxidant effect of Withania somnifera glycowithanolides in chronic footshock stress-induced perturbations of oxidative free radical scavenging enzymes and lipid peroxidation in rat frontal cortex and striatum. J Ethnopharmacol 2001, 74(1):1-6. 10.1016/S0378-8741(00)00309-3, 11137343.
40. Kulkarni SK, George B, Mathur R. Protective effect of Withania somnifera root extract on electrographic activity in a lithium-pilocarpine model of status epilepticus. Phytotherapy Research 1998, 12(6):451-453.
41. Furmanowa M, Gajdzis-Kuls D, Ruszkowska J, Czarnocki Z, Obidoska G, Sadowska A, Rani R, Upadhyay SN. In vitro propagation of Withania somnifera and isolation of withanolides with immunosuppressive activity. Planta Med 2001, 67(2):146-149. 10.1055/s-2001-11494, 11301861.
42. Sharada AC, Solomon FE, Devi PU, Udupa N, Srinivasan KK. Antitumor and radiosensitizing effects of withaferin a on mouse Ehrlich ascites carcinoma in vivo. Acta Oncol 1996, 35(1):95-100. 10.3109/02841869609098486, 8619948.
43. Yu YK, Hamza A, Zhang T, Gu MC, Zou P, Newman B, Li YY, Gunatilaka AAL, Zhan CG, Sun DX. Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 2010, 79(4):542-551. 10.1016/j.bcp.2009.09.017, 19769945.
44. Mathur S, Kaur P, Sharma M, Katyal A, Singh B, Tiwari M, Chandra R. The treatment of skin carcinoma, induced by UVB radiation, using 1-oxo-5 beta,6 beta-epoxy-witha-2-enolide, isolated from the roots of Withania somnifera, in a rat model. Phytomedicine 2004, 11(5):452-460. 10.1016/j.phymed.2003.05.004, 15330502.
45. Kuboyama T, Tohda C, Komatsu K. Withanoside IV and its active metabolite, sominone, attenuate A beta(25-35)-induced neurodegeneration. Eur J Neurosci 2006, 23(6):1417-1426. 10.1111/j.1460-9568.2006.04664.x, 16553605.
46. Tohda C, Kuboyama T, Komatsu K. Search for natural products related to regeneration of the neuronal network. Neurosignals 2005, 23(1-2):34-45.
47. Sreeramulu S, Jonker HRA, Langer T, Richter C, Lancaster CRD, Schwalbe H. The Human Cdc37.Hsp90 Complex Studied by Heteronuclear NMR Spectroscopy. J Biol Chem 2009, 284(6):3885-3896. 10.1074/jbc.M806715200, 19073599.
48. NCBI-PubChem Compound database. , http://pubchem.ncbi.nlm.nih.gov/
49. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 1996, 118(9):2309-2309.
50. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent. Cell 1997, 89(2):239-250. 10.1016/S0092-8674(00)80203-2, 9108479.
51. MacLean M, Picard D. Cdc37 goes beyond Hsp90 and kinases. Cell Stress Chaperon 2003, 8(2):114-119.
52. Shao JY, Irwin A, Hartson SD, Malts RL. Functional dissection of Cdc37: Characterization of domain structure and amino acid residues critical for protein kinase binding. Biochemistry-Us 2003, 42(43):12577-12588.
53. Zhang W, Hirshberg M, McLaughlin SH, Lazar GA, Grossmann JG, Nielsen PR, Sobott F, Robinson CV, Jackson SE, Laue ED. Biochemical and structural studies of the interaction of Cdc37 with Hsp90. J Mol Biol 2004, 340(4):891-907. 10.1016/j.jmb.2004.05.007, 15223329.
54. Roe SM, Ali MMU, Meyer P, Vaughan CK, Panaretou B, Piper PW, Prodromou C, Pearl LH. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 2004, 116(1):87-98. 10.1016/S0092-8674(03)01027-4, 14718169.
55. Prodromou C, Panaretou B, Chohan S, Siligardi G, O'Brien R, Ladbury JE, Roe SM, Piper PW, Pearl LH. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. Embo J 2000, 19(16):4383-4392. 302038, 10944121, 10.1093/emboj/19.16.4383.
56. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998, 19(14):1639-1662.
57. Dym O, Xenarios I, Ke HM, Colicelli J. Molecular docking of competitive phosphodiesterase inhibitors. Mol Pharmacol 2002, 61(1):20-25. 10.1124/mol.61.1.20, 11752202.
58. Rao MS, Olson AJ. Modelling of Factor Xa-inhibitor complexes: A computational flexible docking approach. Proteins 1999, 34(2):173-183. 10.1002/(SICI)1097-0134(19990201)34:2<173::AID-PROT3>3.0.CO;2-F, 10022353.
59. Goodsell DS, Morris GM, Olson AJ. Automated docking of flexible ligands: Applications of AutoDock. J Mol Recognit 1996, 9(1):1-5. 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6, 8723313.
60. Hetenyi C, van der Spoel D. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci 2002, 11(7):1729-1737. 2373668, 12070326, 10.1110/ps.0202302.
61. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. J Comput Aid Mol Des 1996, 10(4):293-304.
62. DeLano W. The PyMOL Molecular Graphics System 2002. 2002, San Carlos, CA: DeLano Scientific.
63. Gupta A, Gandhimathi A, Sharma P, Jayaram B. ParDOCK: An all atom energy based Monte Carlo docking protocol for protein-ligand complexes. Protein Peptide Lett 2007, 14(7):632-646.
64. Case DA DT, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Walker RC, Zhang W, Merz KM, Roberts B, Wang B, Hayik S, Roitberg A, Seabra G, Kolossváry I, Wong IF, Paesani F, Vanicek J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Cai Q, Ye X, Wang J, Hsieh MJ, Cui G, Roe DR, Mathews DH, Seetin MG, Sagui C, Babin V, Luchko T, Gusarov S, Kovalenko A, Kollman PA. AMBER 11. 2010, San Francisco: University of California.
65. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of Simple Potential Functions for Simulating Liquid Water. J Chem Phys 1983, 79(2):926-935.
66. Jakalian A, Bush BL, Jack DB, Bayly CI. Fast, efficient generation of high-quality atomic Charges. AM1-BCC model: I. Method. J Comput Chem 2000, 21(2):132-146.
67. Berendsen HJC, Postma JPM, Vangunsteren WF, Dinola A, Haak JR. Molecular-Dynamics with Coupling to an External Bath. J Chem Phys 1984, 81(8):3684-3690.
68. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical-Integration of Cartesian Equations of Motion of a System with Constraints - Molecular-Dynamics of N-Alkanes. J Comput Phys 1977, 23(3):327-341.
69. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A Smooth Particle Mesh Ewald Method. J Chem Phys 1995, 103(19):8577-8593.